<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01347320</url>
  </required_header>
  <id_info>
    <org_study_id>OsloUH</org_study_id>
    <nct_id>NCT01347320</nct_id>
  </id_info>
  <brief_title>Preoperative Magnetic Resonance (MR) Imaging of Prostate Cancer</brief_title>
  <official_title>Clinical Impact of MR Imaging in Patients With Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators want to evaluate if preoperative MRI improves the surgical results,&#xD;
      especially in respect to surgical margins. The impact on the surgical procedure will be&#xD;
      evaluated.&#xD;
&#xD;
      In addition the investigators will examine the accuracy of tumor detection, localization and&#xD;
      staging.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
      During the last two decades, Magnetic Resonance Imaging (MRI) of the prostate has evolved to&#xD;
      become a promising tool in preoperative evaluation of prostate cancer. Several studies have&#xD;
      evaluated the radiological and histopathological correlation. However, the sensitivity and&#xD;
      specificity in regard to staging have shown wide ranges and poor reproducibility. These&#xD;
      discrepancies can be explained by difference in patient selection, MRI methods, and criteria&#xD;
      used for diagnosis. More studies are therefore needed to evaluate the clinical impact of&#xD;
      preoperative MRI in patients with prostate cancer.&#xD;
&#xD;
      Aims of the study:&#xD;
&#xD;
      To evaluate 1) detection rate of tumor 1-3 (tumor 1 = index tumor), size of tumor 1-3,&#xD;
      possible extraprostatic extension and predict presence of Gleason grade 4 and 5 tumor, 2) the&#xD;
      influence of preoperative MRI on the surgical decision process with respect to the operative&#xD;
      procedure for removal of the gland and pelvic lymph node dissection, and 3) the impact of&#xD;
      preoperative MRI on the rate of positive surgical margins and functional results.&#xD;
&#xD;
      Material and method:&#xD;
&#xD;
      A prospective study including 400 consecutive patients referred to robot assisted&#xD;
      laparoscopic prostatectomy randomised to preoperative MRI (intervention group) and no MRI&#xD;
      (control group). The prostatectomy specimens will be histopathologically examined, and TNM&#xD;
      classification will be performed according to 2002 AJCC standard.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Surgical margins</measure>
    <time_frame>30 days</time_frame>
    <description>The surgical margins are assessed by evaluating the pathological specimen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surgical decision process</measure>
    <time_frame>30 days</time_frame>
    <description>Evaluated using questionaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preoperative TNM classification</measure>
    <time_frame>1-4 weeks</time_frame>
    <description>Based upon preoperative MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of Gleason grade 4 and 5</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional outcome</measure>
    <time_frame>1 year after prostatectomy</time_frame>
    <description>Evaluate the functional outcome in respect to erectile dysfunction.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>No preoperative MRI</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>control arm of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRI group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>preoperative MRI</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Preoperative MRI</intervention_name>
    <description>Preoperative staging</description>
    <arm_group_label>MRI group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  All patients suitable for surgery.&#xD;
&#xD;
          -  Positive biopsy (Gleason grade &gt;3).&#xD;
&#xD;
          -  Informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who do not sign the consent paper for any reason or do not accept the study&#xD;
             premises.&#xD;
&#xD;
          -  Patents who want to withdraw for any reason during the study.&#xD;
&#xD;
          -  Patients with contraindications to MRI (pacemaker, claustrophobia etc) and/or surgery.&#xD;
&#xD;
          -  Patients who have undergone a high quality MRI examination of the prostate at another&#xD;
             radiological center. In this situation the MR examination is evaluated together with&#xD;
             the surgeon but the patient is not included in the study. (In case of a low quality&#xD;
             examinations, we will disregard the findings, and include the patient).&#xD;
&#xD;
          -  If the surgeon finds it unacceptable to perform RALP without MRI, because of various&#xD;
             reasons (eg. patient demand, too high risk etc) the patient will not be included in&#xD;
             the study.&#xD;
&#xD;
          -  If preoperative MRI reveals extensive tumor invasion into adjacent organ (T4) or&#xD;
             skeletal metastases (M1), as these cancer stadiums do not benefit from RALP.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erik Rud, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital, Aker</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0514</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>March 9, 2010</study_first_submitted>
  <study_first_submitted_qc>May 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2011</study_first_posted>
  <last_update_submitted>December 27, 2013</last_update_submitted>
  <last_update_submitted_qc>December 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Erik Rud</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Prostate cancer</keyword>
  <keyword>preoperative staging</keyword>
  <keyword>MRI</keyword>
  <keyword>Free surgical margins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

